Ocugen raises $40 million, funding late-stage blindness gene therapy trials

Ocugen, Inc. entered an agreement for a registered direct offering to raise approximately $40 million in gross proceeds.

The company will sell 20 million shares of common stock to a single healthcare-focused institutional investor. Each share is priced at $2.00.

This financing strengthens the balance sheet to advance three late-stage gene therapy programs targeting blindness. These clinical programs include OCU400, OCU410, and OCU410ST.

Net proceeds will fund working capital, general corporate purposes, and ongoing clinical trials.